Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Drops By 36.9%

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the target of a large drop in short interest during the month of January. As of January 30th, there was short interest totaling 1,603 shares, a drop of 36.9% from the January 15th total of 2,541 shares. Currently, 0.1% of the company’s shares are short sold. Based on an average daily volume of 22,976 shares, the short-interest ratio is presently 0.1 days. Based on an average daily volume of 22,976 shares, the short-interest ratio is presently 0.1 days. Currently, 0.1% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on BOLT. Weiss Ratings restated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Wednesday, January 21st. Zacks Research lowered shares of Bolt Biotherapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 20th. Finally, HC Wainwright set a $7.00 target price on Bolt Biotherapeutics and gave the stock a “buy” rating in a research note on Monday, October 20th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $34.00.

Bolt Biotherapeutics Trading Down 1.6%

Shares of Bolt Biotherapeutics stock opened at $4.92 on Friday. The firm has a market cap of $9.45 million, a PE ratio of -0.22 and a beta of 0.92. Bolt Biotherapeutics has a 1 year low of $4.41 and a 1 year high of $10.50. The company has a debt-to-equity ratio of 0.65, a current ratio of 3.57 and a quick ratio of 3.57. The stock has a fifty day moving average price of $5.76 and a 200-day moving average price of $5.49.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($3.72) EPS for the quarter, topping analysts’ consensus estimates of ($5.07) by $1.35. The company had revenue of $2.17 million during the quarter, compared to the consensus estimate of $0.82 million. Equities research analysts anticipate that Bolt Biotherapeutics will post -1.61 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Squarepoint Ops LLC grew its holdings in Bolt Biotherapeutics by 19.8% during the 3rd quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock valued at $79,000 after buying an additional 2,448 shares in the last quarter. Shay Capital LLC bought a new position in shares of Bolt Biotherapeutics in the third quarter valued at approximately $85,000. Susquehanna International Group LLP purchased a new position in Bolt Biotherapeutics during the third quarter valued at approximately $89,000. Nano Cap New Millennium Growth Fund L P bought a new stake in Bolt Biotherapeutics during the 4th quarter worth approximately $112,000. Finally, Renaissance Technologies LLC lifted its stake in Bolt Biotherapeutics by 92.2% in the 4th quarter. Renaissance Technologies LLC now owns 55,025 shares of the company’s stock worth $301,000 after purchasing an additional 26,400 shares in the last quarter. 86.70% of the stock is owned by institutional investors.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.